DAWNZERA

Trademark usage description

pharmaceutical preparations and substances for the treatment of edema, namely hereditary angioedema; pharmaceuticals in the fields of autosomal domina Read More

Classification Information

Class [005]
Pharmaceutical preparations and substances for the treatment of edema, namely hereditary angioedema; pharmaceuticals in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders.

Classification kind code

Class [042]
Pharmaceutical research and development in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; providing medical and scientific research and medical and scientific research information in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; providing information and data in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders for medical and scientific research purposes.

Classification kind code

Mark Details

Serial Number

2328508

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 256 on 24^th Mar 2025	Notification of Possible Opposition Sent
Submitted for opposition 48 on 7^th Jun 2024	Agent Changed
Submitted for opposition 257 on 23^rd May 2024	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 22^nd May 2024	Formalized
Submitted for opposition 1 on 22^nd May 2024	Created
Submitted for opposition 30 on 28^th Nov 2023	Filed
Submitted for opposition 228 on 28^th Nov 2023	International Registration